WO2006007758A1 - Composition de medecine traditionnelle chinoise pour le traitement de la rhino-sinusite aigue et chronique - Google Patents

Composition de medecine traditionnelle chinoise pour le traitement de la rhino-sinusite aigue et chronique Download PDF

Info

Publication number
WO2006007758A1
WO2006007758A1 PCT/CN2004/000824 CN2004000824W WO2006007758A1 WO 2006007758 A1 WO2006007758 A1 WO 2006007758A1 CN 2004000824 W CN2004000824 W CN 2004000824W WO 2006007758 A1 WO2006007758 A1 WO 2006007758A1
Authority
WO
WIPO (PCT)
Prior art keywords
weight
parts
chinese medicine
traditional chinese
medicine composition
Prior art date
Application number
PCT/CN2004/000824
Other languages
English (en)
Chinese (zh)
Inventor
Zhiquan Zhao
Original Assignee
Zhiquan Zhao
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhiquan Zhao filed Critical Zhiquan Zhao
Priority to PCT/CN2004/000824 priority Critical patent/WO2006007758A1/fr
Publication of WO2006007758A1 publication Critical patent/WO2006007758A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/236—Ligusticum (licorice-root)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/17—Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/57—Magnoliaceae (Magnolia family)
    • A61K36/575—Magnolia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
    • A61K36/634—Forsythia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants

Definitions

  • the present invention relates to a traditional Chinese medicine composition, and more particularly to a traditional Chinese medicine composition for treating acute and chronic nasal apes and a preparation method thereof.
  • Another object of the present invention is to provide a method of preparing the traditional Chinese medicine composition for treating acute and chronic nasal apes.
  • the traditional Chinese medicine composition of the invention is guided by the theory of traditional Chinese medicine, combined with the modern medical knowledge of acute and chronic rhinitis and the latest progress of the treatment of acute and chronic nasal abdomen by Chinese medicine, through clinical observation, screening effective drugs, and developing acute and chronic treatment A new formula for the nose.
  • Xanthium, Xinyishantong is a medicinal herb, white peony, ephedra, peppermint help Xinyi, Xanthium evade exogenous evil, Xuantong lung gas, Lizhi analgesic as a drug, Sakamoto, Astragalus, Forsythia, Wild chrysanthemum, trichosanthin, raw land, salvia, and medlar are adjuvants, and licorice is used to make medicines.
  • Xanthium, sexual Xin, bitter temperature, into the lungs, this medicine is both windy, and can solve the symptoms, hurricane and pain.
  • Xinyi Sexual Xin Wen, into the lungs, stomach, this product hurricane and cold, can rise to the head, the two drugs used to evacuate the evil, Xuantong nose, dampness and pain relief. Supplemented with ephedra and phlegm to promote the lungs, help its all-night force.
  • Mint, light and clear, and sexual ascension help Xinyi Xingzi to evacuate the wind and heat, and the leader.
  • the nose is the lungs, and the lungs are suitable for the nose.
  • the above three herbs are used to help the lungs and evacuate the evil spirits. At the same time, it also directly treats headaches, nasal congestion and sneezing. Astragalus, forsythia, and wild chrysanthemum clear away heat and detoxification, so that the evils of wind and heat can be solved from the surface, and the sputum of headache and headache is treated by Sakamoto. Tianhua powder, Shengdi nourishing yin and moistening, cooling blood and fluid, to the dryness of the sinister hot medicine. Hey, wet the tori. Salvia, blood circulation. All kinds of medicines are combined to strengthen the work of sputum discharge; licorice is used to reconcile various medicines.
  • the traditional Chinese medicine composition of the invention is made of the following raw materials
  • the raw material for preparing the traditional Chinese medicine composition of the present invention further includes the following raw materials: wild chrysanthemum 20-40 parts by weight, top pollen 20-40 parts by weight, rehmannia 30-60 parts by weight
  • the drug substance for preparing the traditional Chinese medicine composition of the present invention further comprises 5-15 parts by weight of licorice, that is:
  • the raw material medicine for preparing the traditional Chinese medicine composition of the present invention is preferably
  • the Xanthium sibiricum in each of the above-mentioned raw material drug compositions is preferably fried.
  • the method of preparing the traditional Chinese medicine composition of the present invention is:
  • the preparation of the traditional Chinese medicine composition of the present invention is carried out in accordance with the formulation of each of the above-mentioned raw material medicinal materials.
  • dosage form such as pills, tablets, granules, oral solutions, capsules, ointments, emulsions, and traditional Chinese medicine films.
  • dosage form is preferably a granule.
  • Conventional excipients used in the preparation of the traditional Chinese medicine composition of the present invention include flavoring agents, dispersing agents, binders, thickeners, lubricants, diluents, disintegrating agents, preservatives and the like.
  • the traditional Chinese medicine composition of the invention has remarkable effects in treating acute and chronic nasal acupoints, has the characteristics of good purulent sputum effect and quick effect, and can act on various links of inflammatory reaction, thereby reducing symptoms of inflammatory reaction and causing inflammation
  • the reaction subsides and has a good anti-inflammatory effect on acute and chronic inflammation; it has different degrees of antibacterial activity against common pathogenic bacteria causing acute and chronic rhinitis and sinusitis; 'For non-specific immune function and specific immune function, Certain promotion.
  • composition of the present invention will be further described in detail below in conjunction with the examples and pharmacodynamic tests.
  • the traditional Chinese medicine composition has swelling of rat ankle caused by carrageenan, increased capillary permeability caused by histamine and serotonin, and leukocyte migration and ratification caused by sodium carboxymethyl cellulose.
  • the subcutaneous cotton granuloma hyperplasia has obvious inhibitory effect. This suggests that the composition acts on multiple parts of the inflammatory response, thereby reducing the symptoms of the inflammatory response and allowing the inflammatory response to resolve. It has good anti-inflammatory effects on acute and chronic inflammation.
  • In vitro bacteriostatic test A total of 106 clinical isolates were selected, among which most strains were resistant to common antibacterial drugs penicillin and streptomycin, and 3 standard strains. The in vitro antibacterial effect of the traditional Chinese medicine composition of the present invention was studied.
  • the drug has different degrees of antibacterial activity against common pathogenic bacteria causing acute and chronic rhinitis and sinusitis, such as Staphylococcus aureus, hemolytic streptococcus, Pseudomonas aeruginosa, Proteus, and Klebsiella.
  • the traditional Chinese medicine composition of the invention has obvious promoting effect on the non-specific immune function-mononuclear macrophage phagocytosis function of mice, and improves the colloidal clearance speed of blood in mice; in the delayed allergic reaction, the traditional Chinese medicine combination of the invention
  • the substance can also increase the degree of swelling of the ear shell after sensitization by DNFB, improve the susceptibility of the normal body to hypersensitivity, and improve its cellular immune function: In the immune organ, the weight of the spleen is increased.
  • humoral immunity hemolysin production in mice with immunocompromised effects induced by cyclophosphamide has a certain effect.
  • the traditional Chinese medicine composition of the present invention has a certain promoting effect on non-specific immune function and specific immune function, including cellular immunity and humoral immunity.
  • In vitro bacteriostatic test of the traditional Chinese medicine composition of the present invention against bud-free anaerobic a total of 24 representative anaerobic bacteria were selected, and the anti-anaerobic activity of the traditional Chinese medicine composition of the present invention was measured, and the nitrous oxide was measured. Azole was used as a positive control.
  • the test results show that the traditional Chinese medicine composition of the present invention has three kinds of sporeless cells. Anaerobic bacteria have a certain inhibitory effect, but its antibacterial activity is much lower than the control drug metronidazole.
  • Prophylactic administration that is, administration 3 days before infection, has a certain protective effect on mice infected with Staphylococcus aureus at a higher dose, and ED 5Q is 14.4 g/Kg. This result is consistent with the results of having anti-S. aureus action in vitro.
  • the sample of the traditional Chinese medicine composition of the present invention was subjected to the following experiment using the clearing paste of Example 10, and the crude drug concentration was 3 g/ml, and the concentrations used below were all expressed as crude drugs.
  • Instrument 72 type spectrophotometer, ordinary optical microscope.
  • Wistar rats weighing 150-190 (173 ⁇ 12) g, male and female, were randomly divided into 5 groups, 10 in each group, respectively, distilled water group, chlorpheniramine group and high, medium and low doses of the samples of the present invention.
  • Group, the drug volume was 10 ml / kg, once a day, for 3 consecutive days.
  • One hour after the last administration the four parts of the back were shaved, respectively, by intradermal injection of 0.1% histamine and 0.1% 5-HT 0.1 ml (two points) to form a hillock, and then immediately injected into the femoral vein 1%.
  • Sapphire blue 4ml/kg.
  • MH M U ller-Hinton
  • MH M U ller-Hinton
  • Streptococcus was inoculated on a chocolate agar plate.
  • strains choose to treat the disease with the drug
  • a total of 109 pathogenic bacteria and some standard strains S. aureus ATCC25925, Escherichia coli ATCC25922, Pseudomonas aeruginosa MCC27853 were isolated from clinical isolates.
  • strains of Staphylococcus aureus There were 21 strains of Staphylococcus aureus, 19 strains of Staphylococcus epidermidis, 3 strains of hemolytic streptococcus, 22 strains of Escherichia coli, 16 strains of Pseudomonas aeruginosa, 15 strains of Proteus, and 13 strains of Klebsiella.
  • the tested strains were identified by the Department of Microbiology, Tongji Medical University and the Laboratory of the Department of Laboratory Medicine, Union Hospital.
  • test bacteria were inoculated separately into the broth and cultured at 37 ° C for 6-8 hours.
  • the sterile cotton swabs were evenly spread on the surface of the agar and cultured at 37 ° C.
  • the size of the inhibition zone was measured after 16-18 h. Judging according to the unified antibiotic drug susceptibility test criteria.
  • test bacteria were inoculated separately into the broth, cultured at 37 ° C for 16-18 h (E. coli and P. aeruginosa culture for 8 h), and then diluted with sterile broth into 1:1000 bacteria solution for use. 2ml of Biyuanjingqing cream with different concentrations (6g/ml, 3g/ml, 1.5g/ml-0.009375 g/ml) was added to 18ml MH medium, shake well and then inverted.
  • the final concentration of the drug in the medium was 0.6g/ml 0.3g/ml 0.15g/ml administrated with the medium, not inoculated).
  • Bacteria) and the test strains were compared to the plate (the medium contained no drug).
  • the experimental bacteria were inoculated with an inoculation loop, and the drug concentration, the bacterial species and the strain number were indicated on the bottom of the plate, and the results were observed after incubating in a 37 °C incubator for 24 hours.
  • MIC is the lowest drug concentration that inhibits bacterial growth.
  • Results The results of the paper-based drug susceptibility test are shown in Table 5. 92% of the clinical pathogens collected in this experiment were sensitive to norfloxacin, all Staphylococcus aureus and 73% of Staphylococcus epidermidis were resistant to penicillin, and 44% of Gram-negative bacilli were resistant to streptomycin.
  • the in vitro antibacterial activity of the traditional Chinese medicine composition of the present invention is shown in Table 6.
  • the traditional Chinese medicine composition of the present invention has different degrees of bacteriostatic action on the test strain, and the MIC 5Q of Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli, Pseudomonas aeruginosa, Proteus and Klebsiella pneumoniae 0.02812, 0.02344, 0.18, 0.09, 0.206>0.6 g/ml; MIC 90 is 0.0375 0.0625 0.42 0.14 >0.6 >0.6 g/ml, respectively, and the MIC range for hemolytic streptococcus is 0.075-0.6 g/ml.
  • the drug control in this experiment did not show bacterial growth, and the test strains grew well, indicating that the drug itself does not contain live bacteria, and the culture conditions meet the test requirements.
  • the traditional Chinese medicine composition of the present invention is a traditional Chinese medicine compound preparation, and has the functions of clearing away heat and detoxifying.
  • a total of 106 clinical isolates (including most of the strains resistant to the commonly used antibacterial drugs penicillin and streptomycin) and 3 standard strains were selected, and the in vitro antibacterial effect of the traditional Chinese medicine composition of the present invention was tested.
  • the drug has various degrees of bacteriostatic action on common pathogenic bacteria causing acute and chronic rhinitis and sinusitis, such as Staphylococcus aureus, hemolytic streptococcus, Pseudomonas aeruginosa, Proteus, and Klebsiella. Results of paper-based drug susceptibility test of clinical isolates against three antimicrobial agents
  • S number of sensitive strains
  • M number of moderately sensitive strains
  • R %: number of resistant strains (percentage of resistant Zhu).
  • mice of 20_24g male and female, were randomly divided into 5 groups, namely distilled water group, Yunzhi polysaccharide positive control group, high, medium and low dose groups of the present invention, each group was 10ml/kg.
  • Shake well in 2 ml of 0.1% sodium carbonate solution measure the optical density at 680 mm wavelength with a 751 ultraviolet spectrophotometer, and calculate the clearance index K value according to the following formula.
  • K (logOD 2 -logOD 10 )/ (t 10 -t 2 ) OD 2 and OD 1Q represent the optical density of the blood samples measured in 2 and 10 minutes, respectively, and t 10 and t 2 represent the measurement time, after the blood collection is completed, small Rats were sacrificed by cervical dislocation, and the liver and spleen weights were weighed separately. Then, the phagocytic index a value was calculated according to the following formula:
  • the K value and the a value of each group were expressed by XSD, and the F test was performed to compare the significance of each group.
  • mice On the sixth day of administration, 1% DNFB solution ⁇ was evenly spread on both sides of the right auricle for attack, and the left ear was used as a control. After 24 hours of attack, the mice were sacrificed by whitening the neck, and the left and right ear shells were cut out. The ear piece with a diameter of 3 mm was removed with a puncher, and the weight of the two ears was the degree of ear swelling. At the same time, the spleen of each mouse was taken out. Weighed with the thymus, weighing spleen (mg) and thymus weight (mg) per 10 g of mice, respectively:
  • Spleen index spleen weight (mg) / body weight (g) X 10
  • Thymus index thymus weight (mg) / body weight (g) X 10
  • the ear shell swelling degree, spleen index and thymus index were tested by F test, and the differences of each group were judged to be significant.
  • the swelling degree of the ear shell of the Tripterygium wilfordii group was 0.49 ⁇ 0.24, which was significantly lower than that of the distilled water group 1.24 ⁇ 0.47. It is consistent with the results reported in the literature that the Tripterygium wilfordii inhibits the delayed allergic reaction, while the traditional Chinese medicine composition of the present invention is in the middle and the middle.
  • the ear shell swelling degree of the low-dose group and the Yunzhi polysaccharide-administered group were 1.83 ⁇ 0.38, 1.66 + 0.38, 2.51, respectively. Both ⁇ 0.36 and 2.31 ⁇ 0.35 were significantly higher than the distilled water group, and the lower dose group was more effective (see Table 8).
  • Cyclophosphamide is a product of Shanghai Twelve Pharmaceutical Factory. The approval number is: Huwei Medicine Zhunzi (1981) No. 0364 (12).
  • SRBC preservation solution glucose 2.05g, sodium chloride 0. 42g, sodium citrate 0.8g, citric acid 0.05g, distilled water 100ml, dissolved and mixed filter, sterilized under 8 pounds pressure for 10 minutes, at 4 ° C saves the spare.
  • Duchen solution (used for the determination of hemoglobin): sodium hydrogencarbonate 1.0 g, high iron cyanide steel, 0.2 g, potassium cyanide 0.05 g plus distilled water 1000 ml.
  • SRBC Under aseptic conditions, take blood from the jugular vein of healthy adult sheep, shake the blood into a triangular beaker with glass beads for 10 minutes to remove fibrin, add 2 times the amount of preservation solution, put 4 °C refrigerator spare, temporarily washed with physiological saline 3 times, 2000 rpm, 10 minutes, to accumulate red blood cells, and then diluted to the required concentration.
  • the eyeballs were removed from the eyelids of the mice, the serum was separated, the serum was diluted 800 times, and the diluted serum 1 ml, 5% SRBC 0.5 ml, 10% complement lml, and 3 ml of Dud solution were added to the test tube in turn, and shaken. After 10 minutes, the absorbance was recorded at a wavelength of 540 nm, and 5% 0.25 ml of SRBC and 4 ml of turbid liquid were added. The absorbance value was recorded. This value is the value of the luminosity of the half hemolysis of the SRBC used in the experiment. The half of the hemolysis value of the sample is calculated by the following formula.
  • Half of the hemolysis value (HC 5G ) absorbance value of the sample X dilution factor
  • Test drug test drug: The sample clearing paste of the embodiment 10 of the present invention contains 3 g of crude drug per ml. Prepare 5000mg/ml with distilled water, sterilize with steam at 100 ° C for 30 min, and dilute with time. Positive control drug: metronidazole, Wuhan Binhu Pharmaceutical Co., Ltd., batch number 960541, formulated into 320ug/ml.
  • test strains and the test strains are isolates of clinical case specimens in Wuhan, including 20 strains of Bacteroides fragilis and 2 strains of Bacillus gingivalis, a total of 3 strains of 24 strains.
  • the tested strains were identified by the bacteria room of the Department of Microbiology, Tongji Medical University.
  • the standard strain (Bacteroides fragilis 5524) was purchased from Beijing Biopharmaceutical Inspection Institute. All strains were lyophilized at -30 ° C, diluted with sterile physiological saline, inoculated in anaerobic separation medium, anaerobic cultured at 37 ° C for 48 h, and then picked up a single colony to be inoculated into anaerobic basal medium. Analyze culture at 37 ° C for 24 h, adjust the bacterial solution to 10 6 cfo / ml. 3. Medium, anaerobic medium, purchased from Shanghai Medical Institute.
  • Test method agar plate dilution method, 5000 mg/ml of the traditional Chinese medicine composition of the present invention and 320 ug/ml metronidazole 2 ml were separately diluted, and the minimum concentrations were 39 mg/ml and 0.3 ug/ml, respectively.
  • the drug concentration, the bacterial species and the strain number were indicated on the bottom of the plate, and the results were observed after 37 hours of anaerobic conditions.
  • the MIC is the lowest drug concentration that inhibits the growth of bacteria.
  • Drug, test drug The clearing paste of the embodiment 10 of the present invention is a sample, a brown liquid, and contains 3 g of crude drug per ml. Mix with different concentrations (0.3, 0.6, 0.9, 1.2, 1.5 g/ml) in distilled water and mix as needed.
  • Control drug Ciprofloxacin lactate injection (200mg/100ml), produced by Guangzhou Qiaoguang Pharmaceutical Factory, batch number 95091502, formulated into 0.3mg/ml with sterile physiological saline.
  • the bacteria used to infect animals are clinically isolated Staphylococcus aureus, which is identified by the bacteria laboratory of the Department of Clinical Laboratory of Tongji Hospital affiliated to Tongji Medical University.
  • Test animals Kunming mice, weighing 18-22 g, male and female, fasting water supply 18 h before the test.
  • the test animals were provided by the Medical Laboratory Animal Center of Tongji Medical University. 5, test methods, according to animal weight, gender stratification random group, each group of 10, a total of 7 groups, namely distilled water negative control, ciprofloxacin (3mg / kg / time) positive control, 5 groups of different doses of this
  • the traditional Chinese medicine composition group of the invention (3, 6, 9, 12, 15 g/Kg/day).
  • the infected animals were intraperitoneally injected with the prepared bacterial solution, 0.5 ml per mouse.
  • the traditional Chinese medicine composition of the present invention is intragastrically administered once every day before infection and 4 days after infection, and ciprofloxacin is intravenously injected immediately after infection and 6 hours after infection, and the negative control group is given equal volume of distilled water, and the administration capacity is 0.1 ml/10 g.
  • the observation time was 7 days, and the number of deaths of each group of mice was recorded, and ED 5 () of the traditional Chinese medicine composition of the present invention was calculated according to the Bliss method.
  • Xanthium is better for frying.
  • Xanthium is better for frying.
  • Xanthium is better for frying.
  • Xanthium is better for frying.
  • the above fourteen flavors, Xinyi, Mint, Sakamoto, and wild chrysanthemums are added with 675ml of water to extract the volatile oil.
  • the distilled aqueous solution and the dregs are collected separately; the other ten herbs are added with water 3800ml to cook for 1. 5 hours, hot filtered
  • the filtered dregs are combined with the above dregs, and then boiled 4500 ml of water for 3 times, each time for 1 hour, filtered, and the combined filtrate and the above-mentioned distilled aqueous solution are concentrated to form a clear paste; finally, the pharmacy is added through a conventional procedure. Acceptable excipients are made into capsules.
  • Xanthium is better for frying.
  • Xanthium is better for frying.
  • Xanthium is better for frying.
  • Xanthium is better for frying.
  • the above fourteen flavors, Xinyi, Mint, Sakamoto, wild chrysanthemum four herbs add 1200ml of water to extract volatile oil, the distilled aqueous solution and dregs are separately collected; the other ten herbs add water 5000ml decoction for 2 hours, hot filtered; The above two kinds of dregs are combined, and then boiled with 6000 ml of water twice, each time for 1 hour, filtered, and the combined filtrate and the above-mentioned distilled aqueous solution are concentrated to form a clear paste; finally, a pharmaceutically acceptable form is added through a conventional procedure. The agent is made into a soft capsule.
  • Xanthium is better for frying.
  • Xanthium is better for frying.
  • Xanthium is better for frying.
  • Xanthium is better for frying.
  • the above eight flavors, Xinyi, Mint, and Sakamoto three kinds of medicines add 400ml of water to extract volatile oil, and the distilled aqueous solution and dregs are collected separately; the other five herbs add water 3000ml to cook for 1.5 hours, hot filtered; The slag is combined, and then decocted with water 3500 ml, once every 0.5 hours, filtered, and the combined filtrate and the above-mentioned distilled aqueous solution are concentrated to form a clear paste; finally, a pharmaceutically acceptable excipient is added through a conventional procedure.
  • the auxiliary material is made into a soft capsule.
  • Xanthium is better for frying.
  • the above thirteen flavors, Xinyi, Mint, Sakamoto, and wild chrysanthemums are added with 800ml of water to extract volatile oil.
  • the distilled aqueous solution and dregs are collected separately; the other nine herbs are boiled in 4000ml for 2 hours, and hot filtered; The above two kinds of dregs are combined, and then boiled twice with water 4000 ml, one hour each time, filtered, and the combined filtrate and the above-mentioned distilled aqueous solution are concentrated to form a clear paste; finally, a pharmaceutically acceptable shape is added through a conventional procedure.
  • the agent is made into a soft capsule.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention concerne une composition de médecine traditionnelle chinoise pour le traitement de la rhion-sinusite aiguë et chronique et la préparation de cette composition, laquelle est élaborée à partir de : Flos Magnoliae Liliflorae, Fructus Xanthii, Herba Ephedrae, Radix Angelicae Dahuricae, Herba Menthae, Rhizoma Ligustici, Fructus Forsythiae, etc. Elle entre dans diverses formes pharmaceutiques cliniquement acceptables, du type granulés, comprimés, solutions pour administration orale, etc. Ladite composition apporte des bienfaits dans le traitement considéré.
PCT/CN2004/000824 2004-07-16 2004-07-16 Composition de medecine traditionnelle chinoise pour le traitement de la rhino-sinusite aigue et chronique WO2006007758A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2004/000824 WO2006007758A1 (fr) 2004-07-16 2004-07-16 Composition de medecine traditionnelle chinoise pour le traitement de la rhino-sinusite aigue et chronique

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2004/000824 WO2006007758A1 (fr) 2004-07-16 2004-07-16 Composition de medecine traditionnelle chinoise pour le traitement de la rhino-sinusite aigue et chronique

Publications (1)

Publication Number Publication Date
WO2006007758A1 true WO2006007758A1 (fr) 2006-01-26

Family

ID=35784855

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2004/000824 WO2006007758A1 (fr) 2004-07-16 2004-07-16 Composition de medecine traditionnelle chinoise pour le traitement de la rhino-sinusite aigue et chronique

Country Status (1)

Country Link
WO (1) WO2006007758A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102274335A (zh) * 2011-05-09 2011-12-14 杨兴周 一种一次性根治鼻炎、鼻窦炎的中草药滴鼻液
CN102614259A (zh) * 2011-06-03 2012-08-01 宋协勘 一种治疗慢性化脓性鼻窦炎的中药
CN102697894A (zh) * 2012-06-04 2012-10-03 韦相炎 一种用于治疗鼻腔炎症性疾病的药物组合物及其制备方法
CN103142709A (zh) * 2013-04-07 2013-06-12 步新源 一种治疗感冒的药物
CN103223019A (zh) * 2013-04-04 2013-07-31 施怀杰 一种治疗鼻炎的中药
CN104189703A (zh) * 2014-07-30 2014-12-10 严中明 一种用于治疗肾元亏虚型流鼻涕病的中药组合物
CN104258318A (zh) * 2014-07-30 2015-01-07 严中明 一种用于治疗肺气虚寒型流鼻涕病的中药组合物
CN104337919A (zh) * 2014-10-15 2015-02-11 四川金堂海纳生物医药技术研究所 一种治疗鼻窦炎的内服药物及其制备方法
CN107496505A (zh) * 2017-09-30 2017-12-22 廖会吉 一种治疗鼻炎、鼻窦炎、鼻息肉肿大的药物及其制备方法
CN107684586A (zh) * 2017-08-27 2018-02-13 钟启义 一种治疗慢性额窦炎的中药

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1265909A (zh) * 1999-03-03 2000-09-13 朱维新 鼻炎胶囊
CN1316251A (zh) * 2000-04-04 2001-10-10 张忠贵 鼻窦炎康复胶囊

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1265909A (zh) * 1999-03-03 2000-09-13 朱维新 鼻炎胶囊
CN1316251A (zh) * 2000-04-04 2001-10-10 张忠贵 鼻窦炎康复胶囊

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102274335A (zh) * 2011-05-09 2011-12-14 杨兴周 一种一次性根治鼻炎、鼻窦炎的中草药滴鼻液
CN102614259A (zh) * 2011-06-03 2012-08-01 宋协勘 一种治疗慢性化脓性鼻窦炎的中药
CN102697894A (zh) * 2012-06-04 2012-10-03 韦相炎 一种用于治疗鼻腔炎症性疾病的药物组合物及其制备方法
CN102697894B (zh) * 2012-06-04 2014-04-30 韦相炎 一种用于治疗鼻腔炎症性疾病的药物组合物及其制备方法
CN103223019A (zh) * 2013-04-04 2013-07-31 施怀杰 一种治疗鼻炎的中药
CN103142709A (zh) * 2013-04-07 2013-06-12 步新源 一种治疗感冒的药物
CN104189703A (zh) * 2014-07-30 2014-12-10 严中明 一种用于治疗肾元亏虚型流鼻涕病的中药组合物
CN104258318A (zh) * 2014-07-30 2015-01-07 严中明 一种用于治疗肺气虚寒型流鼻涕病的中药组合物
CN104337919A (zh) * 2014-10-15 2015-02-11 四川金堂海纳生物医药技术研究所 一种治疗鼻窦炎的内服药物及其制备方法
CN107684586A (zh) * 2017-08-27 2018-02-13 钟启义 一种治疗慢性额窦炎的中药
CN107496505A (zh) * 2017-09-30 2017-12-22 廖会吉 一种治疗鼻炎、鼻窦炎、鼻息肉肿大的药物及其制备方法

Similar Documents

Publication Publication Date Title
US20110318438A1 (en) Pharmacologically effective composition of herbs for treatment on symptoms of influenza and colds
CN101411782B (zh) 一种治疗急性咽炎的药物组合物及其制备方法
CN111317798A (zh) 解毒化湿利咽中药组合物及其应用
WO2021164037A1 (fr) Médicament pour le traitement de la grippe ou d'une maladie infectieuse
CN105560884A (zh) 一种治疗狗肺炎的药物组合物及其制备方法
WO2006007758A1 (fr) Composition de medecine traditionnelle chinoise pour le traitement de la rhino-sinusite aigue et chronique
CN101628108B (zh) 治疗外感风寒的中药颗粒剂及其制备方法
CN1939421A (zh) 一种抗菌、抗病毒的中药组合物
CN107823375A (zh) 一种治疗奶牛乳房炎的中药片剂及其制备方法
CN105343503B (zh) 一种治疗咽喉炎的药物组合物及其应用
TWI352596B (fr)
CN116211993B (zh) 老慢清组合物及其制备方法
CN109381607A (zh) 一种治疗血液病合并细菌感染的药物组合物及其制备工艺
CN103735906A (zh) 一种治疗干性支气管扩张的中药制剂及其制备方法
CN114601807B (zh) 一种贝草清肺浓缩丸的制备方法
CN113304218B (zh) 治疗猫杯状病毒感染的中药
CN113101331B (zh) 一种百里香药茶及其制备方法和应用
CN115089689B (zh) 一种治疗痉挛性咳嗽的中药组合物及其制备方法、应用
CN105535046A (zh) 一种从红丝线鲜草中低温提取有效成分并制备用于保健治疗肺部等炎症的复方剂的方法
CN108143944A (zh) 一种治疗伤风的中药组合物
CN107158062B (zh) 肿瘤辅助治疗药物及其应用
CN105362675A (zh) 一种治疗粉刺性乳痈的乳膏及其制备方法
CN111671808A (zh) 一种抗病毒诺丽sod口腔喷雾剂及其制备方法
CN113559141A (zh) 茵陈蒿用于制备治疗肺纤维化药物的用途
CN112826893A (zh) 一种治疗乳腺增生和乳腺肿瘤的药物及其制备方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase